Developing a cost-effective method for producing proteins used in therapies.
A new platform for inexpensive and scalable recombinant protein and growth factor production to support cell culture applications in therapeutics.
['FUNDING_SBIR_1'] · OPERA BIOSCIENCE, INC. · NIH-10699041
This study is working on a new way to make important proteins for treatments like CAR-T cell therapy using a special bacteria, which could help make these therapies cheaper and easier for patients to get.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OPERA BIOSCIENCE, INC. (nih funded) |
| Locations | 1 site (Evanston, UNITED STATES) |
| Trial ID | NIH-10699041 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a new platform that utilizes a bacterial system to produce growth factors and recombinant proteins more efficiently and at a lower cost. By leveraging the type III secretion system of Salmonella, the project aims to streamline the production process, which is crucial for developing therapies like CAR-T cell treatments. Patients could benefit from more affordable and accessible therapies as a result of this innovative approach to protein production.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include patients requiring therapies that utilize recombinant proteins, such as those undergoing CAR-T cell treatments.
Not a fit: Patients who do not require recombinant protein therapies or those with conditions not addressed by this research may not see any benefit.
Why it matters
Potential benefit: If successful, this research could significantly reduce the costs associated with producing therapeutic proteins, making advanced treatments more accessible to patients.
How similar studies have performed: Previous research has shown promise in using bacterial systems for protein production, indicating that this approach could lead to successful outcomes.
Where this research is happening
Evanston, UNITED STATES
- OPERA BIOSCIENCE, INC. — Evanston, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIANG, JULIE MING — OPERA BIOSCIENCE, INC.
- Study coordinator: LIANG, JULIE MING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.